Siefker-Radtke, Arlene

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer

Kamoun, A., de Reyniès, A., Allory, Y., Sjödahl, G., Robertson, A. G., Seiler, R., Hoadley, K. A., Groeneveld, C. S., Al-Ahmadie, H., Choi, W., et al. (2020) · European Urology

Bladder and Urothelial Cancer TreatmentsBreast Cancer Treatment Studies

Cited by 1,359

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Gao, J., Navai, N., Alhalabi, O., Siefker-Radtke, A., Campbell, M. T., Tidwell, R. S., Guo, C. C., Kamat, A. M., Matin, S. F., Araujo, J. C., et al. (2020) · Nature Medicine

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 318

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer

Wang, L., Saci, A., Szabo, P. M., Chasalow, S. D., Castillo-Martin, M., Domingo-Domenech, J., Siefker-Radtke, A., Sharma, P., Sfakianos, J. P., Gong, Y., et al. (2018) · Nature Communications

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 313

FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.

Siefker-Radtke, A. O., Currie, G., Abella, E., Vaena, D. A., Rezazadeh Kalebasty, A., Curigliano, G., Tupikowski, K., Andric, Z. G., Lugowska, I., & Kelly, W. K. (2019) · Journal of Clinical Oncology

Bladder and Urothelial Cancer TreatmentsFibroblast Growth Factor Research

Cited by 64

Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)

Iyer, G., Siefker-Radtke, A., Milowsky, M., Shore, N., Gao, X., Reimers, M. A., Hahn, N., Cosman, R., Matsubara, N., Necchi, A., et al. (2023) · Cancer Research

Fibroblast Growth Factor ResearchLung Cancer Treatments and Mutations

Cited by 12